Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients [Seeking Alpha]
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $118.00 price target on the stock.
Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer